AD
Osteogenic Growth Peptide, OGP(CAS: 132996-61-3)
CAS Number
Related Products
L-gamma-Glutamylglycine
CAS Number: 1948-29-4
GM-Csf (17-31)
CAS Number: 313219-94-2
Gastrin I Rat
CAS Number: 81123-06-0
![2,2',2''-(10-{2-[4-(3-{[4-({2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethyl}carbamoyl)-6-quinolinyl]oxy}propyl)-1-piperazinyl]-2-oxoethyl}-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid](https://static.chemtradehub.com/structs/237/2370952-98-8-a4fa.webp)
Angiotensin I (1-7)
CAS Number: 51833-78-4
![(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-oxobutanoic acid](https://static.chemtradehub.com/structs/726/72629-65-3-195c.webp)
(3S)-3-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylbutanoyl]amino]-4-methylsulfanylbutanoyl]amino]acetyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-[[(2S)-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
CAS Number: 72629-65-3
Other Suppliers for Osteogenic Growth Peptide, OGP
Basic Information
Molecular Formula
C68H111N23O17
Molecular Weight
1522.75 g/mol
Chemical Identifiers
SMILES
CC(C[C@H](NC([C@@H](N)C)=O)C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(NCC(NCC(O)=O)=O)=O)CC1=CC=CC=C1)=O)=O)CC2=CC=C(O)C=C2)=O)CC(C)C)=O)[C@H](O)C)=O)CCCNC(N)=N)=O)=O)CCC(N)=O)=O)CCCNC(N)=N)=O)CCCCN)=O)C
InChIKey
VNTJGCYVIRTGMZ-PXGLAOGESA-N
Database References
MDL Number
MFCD00214641
FAQ
Osteogenic Growth Peptide (OGP) must comply with regulatory guidelines such as GHS for classification and labeling, REACH for registration, evaluation, and authorization in the European Union, and FDA/EPA requirements for the United States. Specific safety data sheets (SDS) and material safety data sheets (MSDS) must be prepared and distributed to ensure safe handling and use.
In the synthesis of Osteogenic Growth Peptide (OGP), there are several alternatives such as using analogs like Bone Morphogenetic Proteins (BMPs) or other growth factors. Isomers and common alternative reagents like recombinant proteins can also be considered as substitutes to achieve similar biological effects.
The market for Osteogenic Growth Peptide (OGP) is growing due to increasing demand in bone regenerative medicine and orthopedic applications. Research trends are focusing on optimizing delivery methods and exploring its potential in other therapeutic areas like dental and spinal treatments. Price trends indicate a steady market value, reflecting growing interest from both academic and industrial sectors.
Waste containing Osteogenic Growth Peptide (OGP) should be collected in appropriate containers and disposed of through professional waste disposal services. Environmental precautions include ensuring no contamination of soil or water. Incineration is a common method for disposal, but it must be done in compliance with local regulations to prevent air pollution. Chemical neutralization or biological treatment can also be used based on local regulations and environmental impact assessments.
Safety Notice
Please verify product specifications and safety data before use. Contact the supplier for detailed safety information.
Always follow proper handling procedures
Contact Information
Contact Person
Manager Liu
beiputai@163.com
Mobile
15888826472
Telephone
0571-85350119
Visit Website
http://www.beiputaibio.com/Address
Baiyang Street, Qiantang District, No. 600, Building 2, Floor 3, 21st Avenue